Welcome to our dedicated page for SELECT MEDICAL HOLDINGS SEC filings (Ticker: SEM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Select Medical Holdings Corporation SEC filings document the formal disclosures of a NYSE-listed healthcare services company with common stock traded under SEM. Its Form 8-K reports cover operating results and financial condition, material-event disclosures, capital-structure information, employment and compensation-related agreements, and Regulation FD communications.
Proxy materials and annual-meeting filings describe director elections, executive compensation votes, auditor ratification, board-structure proposals, stockholder meeting rights and voting outcomes. The filings also record governance matters and corporate reporting related to Select Medical's hospital and outpatient rehabilitation operations.
Select Medical Holdings Corp director James S. Ely III disposed of 161,674 shares of common stock in connection with the company’s merger. At the effective time of the merger, each share, including previously unvested restricted shares, was converted into the right to receive $16.50 in cash per share, leaving him with no remaining shares.
Select Medical Holdings Corp executive vice president John F. Duggan reported a restructuring of 194,710 shares of common stock linked to a merger. The Form 4 shows his direct holdings in issuer common stock fell to 0 shares after the transaction.
Footnotes explain that immediately prior to the merger’s effective time, he contributed 78,043 common shares and 116,667 restricted shares to Stallion Intermediate Corporation in exchange for equivalent Parent Common Shares and restricted shares, which were then exchanged for equivalent interests in Stallion Group Parent, LP. This reflects a merger-related equity rollover rather than an open-market trade.
Select Medical Holdings executive John Tyler Hollenbach reported a merger-related restructuring of 135,084 common shares. The Form 4 notes these securities were disposed of under an Agreement and Plan of Merger involving Select Medical, Stallion Intermediate Corporation and Stallion MergerSub Corporation.
Immediately before the merger’s effective time, Hollenbach contributed 31,751 common shares and 103,333 restricted shares to Stallion Intermediate Corporation. In return, he received an equivalent amount of Parent common and restricted shares, which were then exchanged for equivalent interests in Stallion Group Parent, LP. Following this restructuring, the Form 4 shows zero Select Medical common shares held directly in this reporting line.
Select Medical Holdings Corp vice chairman David S. Chernow reported merger-related changes in his common stock holdings. A block of 656,823 shares of common stock was converted into the right to receive $16.50 per share in cash as merger consideration.
Immediately before the merger, Chernow contributed 100,000 restricted shares to Stallion Intermediate Corporation in exchange for equivalent restricted shares of Parent, which were then exchanged for interests in Stallion Group Parent, LP. Separately, 113,421 shares were surrendered to satisfy tax withholding obligations tied to restricted stock vesting. Following these transactions, the filing shows no remaining direct holdings of the issuer’s common stock.
SELECT MEDICAL HOLDINGS CORP senior vice president Christopher Weigl reported merger-related changes in his SEM share holdings. His Form 4 shows 12,382 shares of common stock converted into the right to receive $16.50 per share in cash in connection with a merger, plus 1,872 shares surrendered to cover tax withholding on vested restricted stock.
Separately, he contributed 40,000 restricted shares to the merger parent entity in exchange for equivalent interests in Stallion Group Parent, LP. After these transactions, he directly holds 14,524 shares of SELECT MEDICAL common stock. The filing reflects merger consideration, tax withholding, and restructuring steps rather than open-market buying or selling.
Select Medical Holdings Corp’s chief financial officer, Michael F. Malatesta, reported an internal restructuring of 238,057 shares of common stock under a previously signed merger agreement. These securities were contributed to Stallion Intermediate Corporation and converted into equivalent interests in Stallion Group Parent, LP, rather than sold on the open market.
Immediately before the merger’s effective time, Malatesta contributed 79,723 common shares and 158,334 restricted shares to the merger parent entity in exchange for equivalent parent common and restricted shares, which were then exchanged for partnership interests. Following this transaction, his directly held Select Medical common stock position in the issuer was reduced to zero as part of the merger structure.
SELECT MEDICAL HOLDINGS CORP executive vice president Brian R. Rusignuolo reported a restructuring transaction involving 361,370 shares of common stock. The Form 4 shows this was an “other” type of transaction tied to a previously signed merger agreement with Stallion Intermediate Corporation and Stallion MergerSub Corporation.
Immediately before the merger’s effective time, he contributed 203,037 common shares and 158,333 restricted shares to the merger parent in exchange for equivalent parent common and restricted shares, which were then exchanged for interests in Stallion Group Parent, LP. After these steps, the filing reports he directly holds 0 shares of SELECT MEDICAL common stock.
SELECT MEDICAL HOLDINGS CORP’s chief executive officer, Thomas P. Mullin, reported an internal restructuring of 391,709 shares of Common Stock under a previously signed merger agreement. This was not an open‑market trade and carried a reported price of $0.00 per share.
Footnotes explain that immediately before the merger became effective, Mullin contributed 175,042 common shares and 216,667 restricted shares of Select Medical to Stallion Intermediate Corporation, the merger parent. In exchange, he received an equivalent number of parent common and restricted shares, which were then exchanged for interests in Stallion Group Parent, LP.
After this restructuring, the Form 4 shows 0 shares of Select Medical Common Stock held directly by Mullin, with his economic interest shifted into the new parent structure created for the merger.
SELECT MEDICAL HOLDINGS CORP president John A. Saich reported an internal restructuring of his equity stake tied to a merger transaction. The filing shows 736,412 common shares were disposed of at a stated price of $0.00 per share under an Agreement and Plan of Merger with Stallion Intermediate Corporation and Stallion MergerSub Corporation.
Immediately before the merger’s effective time, Saich contributed 519,745 common shares and 216,667 restricted shares to Stallion Intermediate Corporation in exchange for equivalent Parent common and restricted shares, which were then exchanged for interests in Stallion Group Parent, LP. Following this restructuring, the Form 4 reports zero shares of SELECT MEDICAL HOLDINGS CORP common stock held directly.
SELECT MEDICAL HOLDINGS CORP executive vice president Martin F. Jackson reported restructuring his holdings in connection with a merger. On the reported date, he contributed a total of 1,393,957 shares of Select Medical common stock, including indirect holdings by his son and daughter, to Stallion Intermediate Corporation (Parent) under an Agreement and Plan of Merger.
According to the footnotes, 1,138,754 common shares and 244,667 restricted shares were exchanged for equivalent Parent common and restricted shares, which were then exchanged for interests in Stallion Group Parent, LP. Additional blocks of 2,634 common shares were similarly contributed. The filing notes that Jackson beneficially owns the indirectly held securities but disclaims beneficial ownership except to the extent of his pecuniary interest. These are non-market, merger-related conversions rather than open‑market buying or selling.